Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00081627 · ClinicalTrials.gov registry record · Phase 2

Clinical Trial in Patients With Metastatic Colorectal Cancer

A Phase 2 study of Colon Cancer and Rectal Cancer, sponsored by Mast Therapeutics.

Completed
Registry status
Phase 2
Development phase
48
Enrollment target
9
Study locations

NCT00081627: Completed Phase 2 study of Colon Cancer and Rectal Cancer, sponsored by Mast Therapeutics.

NCT00081627 is a Phase 2 study of Colon Cancer and Rectal Cancer that has completed, run by Mast Therapeutics. The registered enrollment target is 48 participants, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower). The trial reports 9 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00081627, a Phase 2 study of Colon Cancer and Rectal Cancer, has completed, sponsored by Mast Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
48 participants
Enrollment target
9
Study locations

Study Summary

The objectives of this trial are to determine if CoFactor in combination with 5-FU are effective in the treatment of metastatic colorectal cancer and to determine the side effects observed with the administration of CoFactor and 5-FU.

Interventions

  • DRUG CoFactor and 5FU

Study Locations (9)

Other

  • CHC Bezanijska Kosa - Belgrade
  • Clinical Center of Serbia - Belgrade
  • Institute for Oncology and Radiology Serbia - Belgrade
  • Institute of Oncology - Sremska Kamenica

California

  • UCSD Moores Cancer Center - La Jolla
  • Mercy General Hospital - Sacramento
  • VA San Diego Healthcare System - San Diego

Michigan

  • Spectrum Health - Grand Rapids

Texas

  • Killeen Cancer Center - Killeen

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2004-04
Est. Completion 2007-01
Phase Phase 2
Mast Therapeutics

9 total trials

What the finished NCT00081627 record still lists

NCT00081627 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Colon Cancer appearing as the primary indexed condition, and to 1 intervention - of which CoFactor and 5FU is the first listed.

NCT00081627 lists 9 locations in 4 states (Other, California, Michigan).

Frequently Asked Questions

What is clinical trial NCT00081627 about?

NCT00081627 is a clinical study titled "Clinical Trial in Patients With Metastatic Colorectal Cancer". The objectives of this trial are to determine if CoFactor in combination with 5-FU are effective in the treatment of metastatic colorectal cancer and to determine the side effects observed with the administration of CoFactor and 5-FU.

What is the current status of trial NCT00081627?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2004-04. Estimated completion is 2007-01.

What conditions does trial NCT00081627 study?

This clinical trial studies the following conditions: Colon Cancer, Rectal Cancer.

What interventions are being tested in trial NCT00081627?

The interventions under investigation include: CoFactor and 5FU (DRUG).

Who is sponsoring clinical trial NCT00081627?

This trial is sponsored by Mast Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00081627 being conducted?

This trial has 9 study locations across California, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colon Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00081627's enrollment target sits among peer trials

48 72nd of 97 higher than 24 of 97 other Colon Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Colon Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00081627, the US trial registry maintained by the National Library of Medicine. NCT00081627 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.